The FDA is approving a breakthrough cancer drug that could have a major impact on how doctors treat more than a dozen cancers. Dr. David Hyman, of Memorial Sloan Kettering in New York City, lead the research on the new drug Larotrectinib [LAH-row-TRECT-tin-nib ].
Hyman says the new drug is based on genetics, including 17 different malignancies which includes lung and breast cancers. As for what is does, Dr. Hyman says patients saw tumors disappear often within days!
Awesome news! You can read more by clicking on the source link below.